Risk of outcomes in COVID-19 oral antiviral initiators compared to non-initiators
| Outcome . | Molnupiravir . | Nirmatrelvir-ritonavir . | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of events/Follow-up (days) | Adjusted hazard ratio (95% CI) | P value for interaction | No. of events/Follow-up (days) | Adjusted hazard ratio (95% CI) | P value for interaction | |||
| Initiators | Non-initiators | Initiators | Non-initiators | |||||
| All-cause mortality | ||||||||
| Overall | 405/128030 | 2551/195799 | 0.895 (0.826–0.970) | 195/133365 | 930/106670 | 0.804 (0.678–0.955) | ||
| Vaccination status | ||||||||
| Unvaccinated | 116/25193 | 1483/82510 | 0.837 (0.754–0.929) | 50/18721 | 402/34180 | 0.839 (0.673–1.046) | ||
| 1 dose | 69/12500 | 515/38141 | 0.962 (0.808–1.147) | 0.05 | 6/5342 | 152/15426 | 0.704 (0.496–0.998) | 0.95 |
| 2 doses | 75/22111 | 315/37083 | 0.963 (0.773–1.199) | 0.15 | 44/22860 | 163/22522 | 0.812 (0.576–1.145) | 0.84 |
| ≥ 3 doses | 145/68226 | 238/38065 | 0.885 (0.653–1.200) | 0.93 | 95/86442 | 213/34542 | 0.817 (0.540–1.235) | 0.30 |
| Sex | ||||||||
| Male | 199/55906 | 1379/94753 | 0.864 (0.773–0.965) | 0.10 | 109/64649 | 467/50730 | 0.838 (0.660–1.063) | 0.88 |
| Female | 206/72124 | 1172/101046 | 0.930 (0.827–1.046) | 86/68716 | 463/55940 | 0.768 (0.599–0.985) | ||
| CCI | ||||||||
| 0–5 | 198/73373 | 1435/118409 | 0.906 (0.814–1.009) | 0.18 | 131/100194 | 558/67095 | 0.913 (0.738–1.130) | 0.17 |
| ≥ 6 | 122/27615 | 604/39155 | 0.918 (0.780–1.081) | 30/13535 | 208/19937 | 0.719 (0.502–1.030) | ||
| Outcome . | Molnupiravir . | Nirmatrelvir-ritonavir . | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of events/Follow-up (days) | Adjusted hazard ratio (95% CI) | P value for interaction | No. of events/Follow-up (days) | Adjusted hazard ratio (95% CI) | P value for interaction | |||
| Initiators | Non-initiators | Initiators | Non-initiators | |||||
| All-cause mortality | ||||||||
| Overall | 405/128030 | 2551/195799 | 0.895 (0.826–0.970) | 195/133365 | 930/106670 | 0.804 (0.678–0.955) | ||
| Vaccination status | ||||||||
| Unvaccinated | 116/25193 | 1483/82510 | 0.837 (0.754–0.929) | 50/18721 | 402/34180 | 0.839 (0.673–1.046) | ||
| 1 dose | 69/12500 | 515/38141 | 0.962 (0.808–1.147) | 0.05 | 6/5342 | 152/15426 | 0.704 (0.496–0.998) | 0.95 |
| 2 doses | 75/22111 | 315/37083 | 0.963 (0.773–1.199) | 0.15 | 44/22860 | 163/22522 | 0.812 (0.576–1.145) | 0.84 |
| ≥ 3 doses | 145/68226 | 238/38065 | 0.885 (0.653–1.200) | 0.93 | 95/86442 | 213/34542 | 0.817 (0.540–1.235) | 0.30 |
| Sex | ||||||||
| Male | 199/55906 | 1379/94753 | 0.864 (0.773–0.965) | 0.10 | 109/64649 | 467/50730 | 0.838 (0.660–1.063) | 0.88 |
| Female | 206/72124 | 1172/101046 | 0.930 (0.827–1.046) | 86/68716 | 463/55940 | 0.768 (0.599–0.985) | ||
| CCI | ||||||||
| 0–5 | 198/73373 | 1435/118409 | 0.906 (0.814–1.009) | 0.18 | 131/100194 | 558/67095 | 0.913 (0.738–1.130) | 0.17 |
| ≥ 6 | 122/27615 | 604/39155 | 0.918 (0.780–1.081) | 30/13535 | 208/19937 | 0.719 (0.502–1.030) | ||
CCI, Charlson mortality index.
Risk of outcomes in COVID-19 oral antiviral initiators compared to non-initiators
| Outcome . | Molnupiravir . | Nirmatrelvir-ritonavir . | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of events/Follow-up (days) | Adjusted hazard ratio (95% CI) | P value for interaction | No. of events/Follow-up (days) | Adjusted hazard ratio (95% CI) | P value for interaction | |||
| Initiators | Non-initiators | Initiators | Non-initiators | |||||
| All-cause mortality | ||||||||
| Overall | 405/128030 | 2551/195799 | 0.895 (0.826–0.970) | 195/133365 | 930/106670 | 0.804 (0.678–0.955) | ||
| Vaccination status | ||||||||
| Unvaccinated | 116/25193 | 1483/82510 | 0.837 (0.754–0.929) | 50/18721 | 402/34180 | 0.839 (0.673–1.046) | ||
| 1 dose | 69/12500 | 515/38141 | 0.962 (0.808–1.147) | 0.05 | 6/5342 | 152/15426 | 0.704 (0.496–0.998) | 0.95 |
| 2 doses | 75/22111 | 315/37083 | 0.963 (0.773–1.199) | 0.15 | 44/22860 | 163/22522 | 0.812 (0.576–1.145) | 0.84 |
| ≥ 3 doses | 145/68226 | 238/38065 | 0.885 (0.653–1.200) | 0.93 | 95/86442 | 213/34542 | 0.817 (0.540–1.235) | 0.30 |
| Sex | ||||||||
| Male | 199/55906 | 1379/94753 | 0.864 (0.773–0.965) | 0.10 | 109/64649 | 467/50730 | 0.838 (0.660–1.063) | 0.88 |
| Female | 206/72124 | 1172/101046 | 0.930 (0.827–1.046) | 86/68716 | 463/55940 | 0.768 (0.599–0.985) | ||
| CCI | ||||||||
| 0–5 | 198/73373 | 1435/118409 | 0.906 (0.814–1.009) | 0.18 | 131/100194 | 558/67095 | 0.913 (0.738–1.130) | 0.17 |
| ≥ 6 | 122/27615 | 604/39155 | 0.918 (0.780–1.081) | 30/13535 | 208/19937 | 0.719 (0.502–1.030) | ||
| Outcome . | Molnupiravir . | Nirmatrelvir-ritonavir . | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of events/Follow-up (days) | Adjusted hazard ratio (95% CI) | P value for interaction | No. of events/Follow-up (days) | Adjusted hazard ratio (95% CI) | P value for interaction | |||
| Initiators | Non-initiators | Initiators | Non-initiators | |||||
| All-cause mortality | ||||||||
| Overall | 405/128030 | 2551/195799 | 0.895 (0.826–0.970) | 195/133365 | 930/106670 | 0.804 (0.678–0.955) | ||
| Vaccination status | ||||||||
| Unvaccinated | 116/25193 | 1483/82510 | 0.837 (0.754–0.929) | 50/18721 | 402/34180 | 0.839 (0.673–1.046) | ||
| 1 dose | 69/12500 | 515/38141 | 0.962 (0.808–1.147) | 0.05 | 6/5342 | 152/15426 | 0.704 (0.496–0.998) | 0.95 |
| 2 doses | 75/22111 | 315/37083 | 0.963 (0.773–1.199) | 0.15 | 44/22860 | 163/22522 | 0.812 (0.576–1.145) | 0.84 |
| ≥ 3 doses | 145/68226 | 238/38065 | 0.885 (0.653–1.200) | 0.93 | 95/86442 | 213/34542 | 0.817 (0.540–1.235) | 0.30 |
| Sex | ||||||||
| Male | 199/55906 | 1379/94753 | 0.864 (0.773–0.965) | 0.10 | 109/64649 | 467/50730 | 0.838 (0.660–1.063) | 0.88 |
| Female | 206/72124 | 1172/101046 | 0.930 (0.827–1.046) | 86/68716 | 463/55940 | 0.768 (0.599–0.985) | ||
| CCI | ||||||||
| 0–5 | 198/73373 | 1435/118409 | 0.906 (0.814–1.009) | 0.18 | 131/100194 | 558/67095 | 0.913 (0.738–1.130) | 0.17 |
| ≥ 6 | 122/27615 | 604/39155 | 0.918 (0.780–1.081) | 30/13535 | 208/19937 | 0.719 (0.502–1.030) | ||
CCI, Charlson mortality index.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
